An Open Label, Multicenter Phase I Study To Evaluate Safety and Efficacy of P276-00 [P 276] in Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 26 Jan 2013
At a glance
- Drugs P 276 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Piramal Phytocare
- 01 May 2009 Piramal Life Sciences Limited added as sponser and affiliate as reported by ClinicalTrials.gov.
- 01 May 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 16 Dec 2008 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.